Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Characterization of safety pharmacology of WT BMP9 in rats. by Tobias G. Schips (21799838)

Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018. by Getachew Ossabo Babore (10788843)

Antibody responses and FRT pathology are comparable between WT and <i>Bhlhe40</i>^<i>-/-</i> mice. by Miguel A. B. Mercado (17847533)

MiR-132-3p was downregulated in TGF-<i>β</i>1 stimulated Met-5A cells and miR-132-3p mimics and miR-132-3p inhibitor transfected Met-5A cells. by Yangyang Yin (14323701)

Subjects:

Two conformationally distinct α-synuclein oligomers share common epitopes and the ability to impair long-term potentiation - Fig 5 by Femke van Diggelen (6499112)

Spatial representation of mean annual soil loss increase/decrease derived with the different modeling centers (rows) and time steps (columns) with the SSP5-8.5. by Fabián Santos (8174028)

List of DESs prepared in this work. by Hossam K. Abdrabou (16436541)

Subjects:

Schematic diagram of the micro-reaction calorimeter [21]. by Hossam K. Abdrabou (16436541)

Subjects:

Effects of vidarabine, V2E, V3E and V5E on AC activity in the heart of WT and AC5KO mice. by Kenji Suita (750993)

“…<p>(A) Vidarabine (Vida), V2E, V3E and V5E similarly and significantly decreased ISO (50 µmol/L)-stimulated AC activity in the WT heart in a dose-dependent manner. …”

Comparison of SF-36 scores of participants with residual limb pain with a VAS score ≥5 and participants with a VAS score <5. by Martin C. Berli (9427264)

ECE decreases coronavirus RNA in a dose dependent manner. by Siyun Lee (17087351)

A genetic variant in human FIRE is associated with a decreased interferon response in myeloid cells. by Anaïs Assouvie (9600529)

One-step and multi-step growth curves each mutant and SVA-WT. by Hai-Fan Zhao (15990862)

DDX3 levels are not decreased in MCMV-infected cells. by Olha Puhach (9500132)

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”